{
  "docId": "019de075-a5cb-73ea-a4ef-8f4a27a8a7b0",
  "docSlug": "2296286e07283457e97b21dc9ce59469",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 46 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 27,
  "pageCount": 46,
  "prevPage": 26,
  "nextPage": 28,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "Includes a process diagram showing the mechanism of action of IMX-110 in tumor microenvironments.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0/27",
  "deckHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0",
  "deckJsonHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0.json",
  "deckAnchorHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0#slide-27",
  "components": [
    {
      "bbox": {
        "h": 0.07,
        "w": 0.9,
        "x": 0.05,
        "y": 0.58
      },
      "kind": "callout",
      "text": "Scientific Basis: IMX-110 turns “cold” tumors “hot” in genetic (KPC) mouse models of pancreatic cancer",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6e2e2120-f462-409a-a937-ab517b26ba37",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.96,
        "x": 0.02,
        "y": 0.73
      },
      "kind": "diagram",
      "text": "Mechanism of action: Eliminating T-regs -> enabling T-lymphocytes -> eliminating vascularization.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "56ef253e-fb8c-48a3-b77d-92c4f0704175",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.08,
        "y": 0.18
      },
      "kind": "image",
      "text": "BeiGene, ImmixBio, Novartis logos",
      "attrs": null,
      "subkind": "logo-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e7cbc156-617c-4f7e-bc14-9e403cf639f9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.02,
        "y": 0.33
      },
      "kind": "list",
      "text": "Study Goal: Demonstrate potential for TSTx in solid tumors; Rapid expansion into oncology indications.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "035b6396-1eac-4379-bb6c-3b94ff471a15",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.25,
        "x": 0.68,
        "y": 0.33
      },
      "kind": "list",
      "text": "Joint Alliance Committee: Coordinate clinical trial.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b423282-50cd-49bf-a70f-22643d4374ad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.25,
        "x": 0.38,
        "y": 0.33
      },
      "kind": "list",
      "text": "Combination Trial Design: IMX-110 + tislelizumab; 30 patient Phase 1b study.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e50b5718-3d72-41e9-9b14-b83ee607b908",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "paragraph",
      "text": "As of June 2021, in China, tislelizumab has been approved in 5 cancer indications.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "22b4b43f-c9c1-4b3a-aaae-13353ab3bfd4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.67
      },
      "kind": "paragraph",
      "text": "IMX-110 + murine anti-PD-1 survival exceeded by exactly 50% a 4-drug combination in a genetic pancreatic cancer (KPC) mouse model.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a91e242c-31c4-4b90-8d10-4a66f8859904",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "Clinical Trial and Supply Agreement with BeiGene for Tislelizumab (Anti-PD-1 mAb)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2d958480-58a7-41c5-bc2b-d9b519b173c9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "59cb2c99-dae3-4b30-b1a7-b9d3c1942108",
      "evidence": "The slide uses a multi-step flow diagram to explain the scientific mechanism of action.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}